Myeloma 2017 | The future of immunotherapy in multiple myeloma
There is a plethora of therapies available for multiple myeloma (MM). In this insightful panel discussion at the Myeloma 2017 meeting in Edinburgh, UK, Ivan Marques Borrello, MD from John Hopkins School of Medicine, Baltimore, MD, Hearn Cho, MD, PhD from Mount Sinai School of Medicine, New York, NY and Tuna Mutis, MD, PhD from the VU University Medical Center, Amsterdam, Netherlands, discuss the current state of immunotherapy for MM and what the future holds. They share their thoughts on combination therapies, creating more broadly applicable therapies, checkpoint inhibitor trials and bispecific antibodies.
Get great new content delivered to your inboxSign up